Other languages Sio Gene Therapies Inc. Nasdaq

Equities

SIOX

US8293991043

Delayed Nasdaq Other stock markets 20:58:58 07/02/2024 GMT			5-day change	1st Jan Change
0.478 ^USD	+1.70%		+22.88%	+29.19%

2023	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index	CI
2023	Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23
Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours	14/12/22
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22
Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	11/08/22
Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	14/06/22
Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	14/06/22
Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value	26/04/22
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/02/22
Health Care Stocks Back Near Even For Tuesday Trading	01/02/22
Sector Update: Health Care	01/02/22
Sio Gene Therapies Ends Gene Therapy Program for Parkinson's Disease, Names New CEO	01/02/22
Sio Gene Therapies Terminates Oxford Biomedica's Parkinson's Disease Gene Therapy Program	01/02/22
Sio Gene Therapies Inc. Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis	31/01/22
Sio Gene Therapies Inc. Announces Executive Changes	31/01/22
Sio Gene Therapies Inc. Appoints David Nassif, J.D. to Its Board of Directors	31/01/22
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/11/21
Sio Gene Receives US Food and Drug Administration's Fast Track Designation for GM2 Gangliosidosis Gene Therapy	01/11/21
Sio Gene Therapies : Chief Research and Development Officer Gavin Corcoran to Leave Next Month; Unveils Chief Medical Officer Role	21/10/21
Sio Gene Therapies : Health Care Stocks Little Changed Despite Moderate Rise by Biotechs	21/10/21
Sio Gene Therapies : Secures FDA Fast Track Designation for Gene Therapy Candidate for GM1 Gangliosidosis	21/10/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sio Gene Therapies Inc. Nasdaq

Equities

SIOX

US8293991043

Other languages

Filters